Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19426112 | 0.84 | CYP1A2 (0.38) | CYP1A2CYP2C9ALOX15ALOX12CYP2C19 | |
| SCHEMBL19426173 | 0.83 | ADRB1 (0.43) | CYP1A2SMN1; SMN2HIF1AHSD17B10KMT2A | |
| SCHEMBL19426176 | 0.75 | KMT2A (0.33) | CYP1A2ALOX15ALOX12CYP2C19SMN1; SMN2 | |
| SCHEMBL19426175 | 0.69 | FFAR2 (0.34) | FFAR2 | |
| SCHEMBL15631294 | 0.68 | GABRA1 (0.59) | CYP1A2CYP2C9ALOX15ALOX12CYP2C19 | |
| SCHEMBL19426172 | 0.68 | ADRA2A (0.46) | HSD17B10 | |
| SCHEMBL19426179 | 0.67 | POLB (0.41) | CYP1A2CYP2C9ALOX15ALOX12CYP2C19 | |
| SCHEMBL15495178 | 0.66 | ALDH1A1 (0.51) | TTR | |
| SCHEMBL11157172 | 0.66 | HSD17B10 (0.43) | CYP1A2CYP2C9ALOX15ALOX12CYP2C19 | |
| SCHEMBL19426110 | 0.66 | ADRB1 (0.45) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | CYP1A2 184/4885CYP2C9 180/4885ALOX15 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.